Análisis de la acción Theriva Biologics Inc (TOVX)TOVXTheriva Biologics Inc

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Theriva Biologics Inc is a good buy right now due to its recent clinical trial advancements and improving financial metrics. The stock is currently priced at $0.25, with a recent RSI of 62.1 indicating bullish momentum. Additionally, the company reported a narrowed net loss of $2.04 million in Q1 2026, down from $4.32 million the previous year, showcasing improved operational efficiency. The main risk is the company's historical volatility, as it has experienced a 39.9% decline over the past year, which could impact investor sentiment.